Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
ATM and ATR inhibitors act on ataxia telangiectasia mutated (ATM) and ATM and Rad3-related (ATR) kinases. The ATM gene was cloned in 1995 and encodes a protein similar to phosphatidylinositol 3-kinase (PI3K). ATR was cloned in 1996 as a candidate human cell cycle checkpoint protein. ATM responds mainly to DNA double-strand breaks, whereas ATR is activated by stalled replication forks. KU-55933, described in 2004 as a specific ATM inhibitor, is joined by KU-60019 and AZD0156. Ceralasertib, VE-821 and BAY-1895344 inhibit ATR and are used to study replication stress. Broader inhibitors of PI3K-related kinases, such as wortmannin, also appear in this list. Inhibitors of DNA-dependent protein kinase are listed in the sibling category DNA-PK.
ATR-IN-30 is a selective ATR (ataxia telangiectasia and Rad3-related protein) ligand that plays a crucial role in disrupting ATR signaling pathways. This compound can be utilized for the development of ATR PROTACs, including PROTAC ATR degrader-2, facilitating targeted protein degradation studies. ATR-IN-30 is valuable for researchers investigating DNA damage response mechanisms and potential therapeutic avenues in cancer treatment.
Out of stock
All 3 sizes
ATR Ligand 2 targets the ATR protein as a PROTAC ligand, facilitating the degradation of ATR through the ubiquitin-proteasome system. By conjugating ATR Ligand 2 with an E3 ligase ligand and linker, researchers can synthesize PROTAC ATR degrader-3, enabling the selective modulation of ATR levels in cells. This compound is instrumental for studies focusing on DNA damage response, cancer therapeutics, and the mechanism of action of DNA-targeting agents.
Out of stock
All 3 sizes